Of all the tick-borne diseases circulating in the United States this summer, Rocky Mountain spotted fever kills most reliably and most quickly. While Lyme disease causes more total infections and H5N1 bird flu generates more headlines, RMSF is the tick-borne disease that kills patients before physicians suspect what they are treating — often because a life-saving antibiotic was started too late.
A study published in February 2026 in the CDC's journal Emerging Infectious Diseases analyzed 500 pediatric RMSF cases hospitalized in Sonora, Mexico over two decades and found an overall case fatality rate of 19.8% — and established that the single most critical factor separating survivors from fatalities was whether doxycycline was administered within five days of symptom onset. This is not a borderline finding. It is the clearest evidence yet that the window for preventing death from RMSF is defined not by how sick the patient becomes, but by how quickly the right antibiotic is started.
